Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$30,700.00

Metal Catalyzed Dynamic Exchange Approach to 14-C Labeled Pharmaceuticals_x000d_

EF 2020-21

Résumé
This CRD proposal will support the research collaboration between Prof. Arndtsen at McGill University and Dr. Gauthier at Merck. The research is directed towards creating a more efficient method to generate carbon-14 radiolabeled pharmaceuticals. Radiolabeled drugs, and in particular those incorporating carbon-14, are required for all molecules in the clinical development. These labeled materials are used to track the drug's fate, toxicity, lifetime, and metabolism within the body. Such analyses are performed thoughout phase 1 through phase 3 clinical trials, and are necessary for the ultimate approval of drugs by regulatory agencies. The use of carbon-14 allows the drug structure to be labeled without changing its actual chemical structure, which is critical to avoid changing the behavior of the material. Unfortunately, the preparation of many carbon-14 labeled materials involves a long synthesis with radioactive material, limiting access to these materials in the timely fashion often needed by the pharmaceutical industry. The project here exploits two significant discoveries emerging from the Arndtsen (McGill) and Gauthier (Merck) groups in the past year, which demonstrate the ability of metal catalysts to mediate the exchange of covalent bonds in organic compounds. These will be used to develop a new and efficient new way to access carbon-14 radiolabeled drugs: via the direct exchange of carbon-14 into carboxylic acids on already prepared pharmaceutical candidates. Overall, the process would offer a versatile method to create carbon-14 labeled pharmaceuticals, and has significant potential for commercial impact in Merck's ability to clinically validate drugs.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
543917-2019
Name nom
Arndtsen, Bruce
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
30700
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Installment
inst:2 - 2
Partie
1
Nb partie
2
Application title
Metal Catalyzed Dynamic Exchange Approach to 14-C Labeled Pharmaceuticals_x000d_
Keyword
NSERC
Application summary
This CRD proposal will support the research collaboration between Prof. Arndtsen at McGill University and Dr. Gauthier at Merck. The research is directed towards creating a more efficient method to generate carbon-14 radiolabeled pharmaceuticals. Radiolabeled drugs, and in particular those incorporating carbon-14, are required for all molecules in the clinical development. These labeled materials are used to track the drug's fate, toxicity, lifetime, and metabolism within the body. Such analyses are performed thoughout phase 1 through phase 3 clinical trials, and are necessary for the ultimate approval of drugs by regulatory agencies. The use of carbon-14 allows the drug structure to be labeled without changing its actual chemical structure, which is critical to avoid changing the behavior of the material. Unfortunately, the preparation of many carbon-14 labeled materials involves a long synthesis with radioactive material, limiting access to these materials in the timely fashion often needed by the pharmaceutical industry. The project here exploits two significant discoveries emerging from the Arndtsen (McGill) and Gauthier (Merck) groups in the past year, which demonstrate the ability of metal catalysts to mediate the exchange of covalent bonds in organic compounds. These will be used to develop a new and efficient new way to access carbon-14 radiolabeled drugs: via the direct exchange of carbon-14 into carboxylic acids on already prepared pharmaceutical candidates. Overall, the process would offer a versatile method to create carbon-14 labeled pharmaceuticals, and has significant potential for commercial impact in Merck's ability to clinically validate drugs.